SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innov...
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an inn...
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innova...
Financial Performance: Strong Year-over-Year Improvement - Total Revenue: RMB 407.2 million, in...
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association f...
SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biop...
* Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diff...
SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innov...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of g...
SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innov...
* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue fro...
SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovatio...
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both sol...
* This approval marks the second international marketing authorization for sugemalimab outside of...
* Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash re...
* Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved inEurope for...
* EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demo...
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor...
* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * H...
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of g...